Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 13 min 36 sec ago

SafeWire, LLC Receives 510(k) Clearance for Y-Wire(R) 2

Tue, 06/03/2014 - 12:52
COOPER CITY, Fla., June 3, 2014 /PRNewswire-iReach/ -- SafeWire, LLC, a medical device company focused on the design and development of devices for minimally invasive spine surgery, announced today that it has received 510(k) clearance from the U.S. Food a...
Devices, Orthopaedic, Neurosurgery, FDA
SafeWire, Y-Wire 2, guidewire, spine surgery

Calhoun Vision Adds AngioDynamics President and CEO to Board of Directors

Tue, 06/03/2014 - 12:46
Joseph M. DeVivo Tapped Based on Strong Track Record of Business Growth PASADENA, Calif.--(Healthcare Sales & Marketing Network)--Calhoun Vision, the developer of groundbreaking ocular technology designed to allow cataract surgeons to adjust the power o...
Devices, Ophthalmology, Personnel
Calhoun Vision, Light Adjustable Lens, intraocular lens

Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President

Tue, 06/03/2014 - 12:40
LOS ANGELES, June 03, 2014 -- (Healthcare Sales & Marketing Network) -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment of neurological and ne...
Devices, Neurology, Personnel
NeuroSigma, Monarch eTNS, trigeminal nerve stimulation

Curis Announces Executive Management Transition

Tue, 06/03/2014 - 12:36
LEXINGTON, Mass., June 3, 2014 -- (Healthcare Sales & Marketing Network) -- Curis, Inc. (CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced the appointment of Ali Fattaey, Ph.D. as the C...
Biopharmaceuticals, Oncology, Personnel
Curis, Erivedge

Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer

Tue, 06/03/2014 - 12:31
MELBOURNE, Australia and STAMFORD, Connecticut, June 3, 2014 -- (Healthcare Sales & Marketing Network) -- Spinifex Pharmaceuticals, a pain drug development company, today announces that it has appointed Dr Ronald Marcus as Chief Medical Officer. Dr Marcus...
Biopharmaceuticals, Personnel
Spinifex Pharmaceuticals, EMA401

Covidien Announces CE Mark of Nellcor(TM) Respiration Rate Technology

Tue, 06/03/2014 - 12:26
System monitors respiration rate, oxygen saturation and pulse rate from a single, finger sensor DUBLIN, Ireland--(Healthcare Sales & Marketing Network)--Covidien plc, a leading global provider of health care products and recognized innovator in patient ...
Devices, Monitoring, Regulatory
Covidien, Nellcor, Respiratory Sensor

Doctors at Community Cancer Center Treat Inoperable Lung Cancer Using TrueBeam System for Image-Guided Radiotherapy and Radiosurgery

Mon, 06/02/2014 - 20:23
NORMAL, Ill., June 2, 2014 -- (Healthcare Sales & Marketing Network) -- When a diagnostic chest X-ray revealed a nodule on his left lung, Paul Hoffman, 79, had a biopsy and soon got bad news: it was Stage 1 lung cancer. He was given two options. The fir...
Devices, Oncology
Varian Medical Systems, radiosurgery, TrueBeam, RapidArc, radiotherapy

Myriad myPath(TM) Melanoma Test Improves the Reliability of Melanoma Diagnosis

Mon, 06/02/2014 - 20:05
Pivotal Clinical Validation Data Presented at the 50th ASCO Annual Meeting SALT LAKE CITY, June 2, 2014 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics, Inc. (MYGN) today presented results from a pivotal clinical validation study of the Myr...
Diagnostics, Dermatology, Oncology
Myriad Genetics, myPath, Melanoma test, malignant melanoma

Myriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO

Mon, 06/02/2014 - 19:56
myRisk Solves Overlap Dilemma Between Hereditary Cancer Syndromes SALT LAKE CITY, June 2, 2014 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics, Inc. (MYGN) today presented several clinical studies on the Myriad myRisk(TM) Hereditary Cancer ...
Diagnostics, Oncology
Myriad Genetics, myRisk, Hereditary Cancer test, hereditary cancer

Omeros Receives FDA Approval of Omidria(TM) for Use in Cataract and Other Intraocular Lens Replacement Procedures

Mon, 06/02/2014 - 19:43
Omeros to Host Conference Call Today at 4:30 p.m. ET SEATTLE, June 2, 2014 -- (Healthcare Sales & Marketing Network) -- Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ...
Biopharmaceuticals, Ophthalmology, FDA
Omeros Corp, Omidria, PharmacoSurgery

Uroplasty Strengthens Board of Directors with Addition of Kevin H. Roche

Mon, 06/02/2014 - 19:38
Roche Brings Deep Healthcare Industry and Business Strategy Experience MINNEAPOLIS, June 2, 2014 -- (Healthcare Sales & Marketing Network) -- Uroplasty, Inc. (UPI) a medical device company that develops, manufactures and markets innovative proprietary ...
Devices, Urology, Personnel

Toshiba’s Aquilion ONE Family Puts Customers First with the Industry’s Only Scalable Premium CT Solution

Mon, 06/02/2014 - 11:59
Unmatched Flexibility and Clinical Capabilities Designed for the New Healthcare Environment TUSTIN, Calif.--(Healthcare Sales & Marketing Network)--Leading healthcare providers now have a scalable top-tier CT solution with the launch of Toshiba America ...
Devices, Radiology, Product Launch
Toshiba America Medical Systems, CT, Aquilion ONE

Orion and Bayer enter global agreement for development and commercialization of novel prostate cancer treatment - Orion upgrades full-year outlook for 2014

Mon, 06/02/2014 - 11:52
Orion and Bayer enter global agreement for development and commercialization of novel prostate cancer treatment Orion upgrades full-year outlook for 2014 ESPOO, Finland, June 2, 2014 -- (Healthcare Sales & Marketing Network) -- Orion Corporation (Nas...
Biopharmaceuticals, Oncology
Orion Corp, Bayer HealthCare, ODM-201, prostate cancer

Guardant Health Announces US Commercial Launch of Guardant360(TM): A Breakthrough Blood Test for Real-Time Cancer Patient Treatment Management

Fri, 05/30/2014 - 14:51
Validation Data on More Than 300 Patients to be Released at the 2014 American Society of Oncology (ASCO) Annual Meeting REDWOOD CITY, Calif., May 30, 2014 -- (Healthcare Sales & Marketing Network) -- Guardant Health, a healthcare company focused on the...
Diagnostics, Oncology, Product Launch
Guardant Health, Guardant360, Digital Sequencing

Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.

Fri, 05/30/2014 - 13:00
SEATTLE, May 30, 2014 -- (Healthcare Sales & Marketing Network) -- Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing to market novel targeted therapies for blood-...
Biopharmaceuticals, Oncology
Cell Therapeutics, CTI BioPharma, PIXUVRI, pixantrone

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong